[Hepatitis associated aplastic anemia during SARS-CoV-2 pandemic]

Area of Science:

• Hematology
• Immunology
• Infectious Diseases

Background:

• Hepatitis-associated aplastic anemia (HAAA) is a rare acquired bone marrow failure syndrome, accounting for 2-5% of aplastic anemia cases in Western countries.
• Standard HAAA treatment involves immunosuppression, particularly when bone marrow transplantation is not feasible.
• The COVID-19 pandemic introduced new treatment considerations, including restrictions on antithymocyte globulin (ATG) use due to potential adverse effects on COVID-19 prognosis.

Purpose of the Study:

• To present a case of a young, otherwise healthy male diagnosed with HAAA.
• To illustrate a personalized treatment approach for HAAA during the SARS-CoV-2 pandemic.
• To demonstrate adherence to updated clinical recommendations regarding immunosuppressive therapy.

Main Methods:

• Diagnosis of hepatitis-associated aplastic anemia in an 18-year-old male.
• Implementation of a modified immunosuppressive treatment regimen.
• Adherence to SARS-CoV-2 pandemic-related guidelines restricting ATG administration.

Main Results:

• The patient received a personalized treatment plan tailored to current pandemic restrictions.
• The case highlights the successful adaptation of HAAA treatment protocols.
• No adverse events related to the modified treatment were reported in the context of the pandemic.

Conclusions:

• Personalized immunosuppressive therapy can be effectively administered for HAAA even with pandemic-related treatment modifications.
• Clinical guidelines must be adapted to ensure patient safety during global health crises.
• This case underscores the importance of individualized patient management in hematological disorders.